Botulinum toxine in the treatment of pain;Botulinumtoxin in der schmerztherapie

Aktuelle Neurologie

Volumn 29, Issue 8, 2002, Pages 389-401

  Probst, T ^a   Dressler, D ^a   Benecke, R ^a   Kunesch, E ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN;

ANALGESIA; ANUS FISSURE; AUTONOMIC DYSFUNCTION; DYSTONIA; ENDPLATE POTENTIAL; ESOPHAGUS ACHALASIA; FIBROMYALGIA; HUMAN; HYPERACTIVITY; MIGRAINE; MUSCLE HYPERTONIA; MYOFASCIAL PAIN; NEUROMUSCULAR SYSTEM; PAIN; PATHOPHYSIOLOGY; REGULATORY MECHANISM; REVIEW; SPASTICITY; SYNDROME DELINEATION; TENSION HEADACHE;

EID: 0036775311     PISSN: 03024350     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-34965     Document Type: Review

References (121)

1. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. J Pediadr Ophthalmol Strabismus 1980; 17: 21-25
2. Aoki K. Pharmacology and immunology of botulinum toxin serotypes. J Neurol 2001; 248 (Suppl 1): 3-10
3. Dressler D. Botulinum Toxin Therapy. Stuttgart, New York: Thieme, 2000
4. Jost W, Kohl A. Botulinum toxin: Evidence-based medicine criteria in rare indications. J Neurol 2001; 248 (Suppl 1): 39-44
5. Brin MF, Fahn S, Moskowitz C et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Adv Neurol 1988; 50: 599-608
6. Brin MF, Lew M, Adler C et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 1999; 53: 1431-1438
7. Hilker R, Schischniaschvili M, Ghaemi M et al. Health related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystonia. J Neurol Neurosurg Psychiatry 2001; 71: 193-199
8. Kelm S, Gerats G, Chalkiadaki A, Hefter H. Reduction of pain and muscle spasms by botulinum toxin A. Nervenarzt 2001; 72: 302-306
9. Lew MF, Adornato BT, Duane DD et al. Botulinum toxin type B: A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 1997; 49: 701-707
10. Poewe W, Deuschl G, Nebe A et al. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled dose ranging study using dysport. J Neurol Neurosurg Psychiatry 1998; 64: 13-17
11. Tarsy D, First ER. Painful cervical dystonia: Clinical features and response to treatment with botulinum toxin. Mov Disord 1999; 14: 1043-1045
12. Chalkiadaki A, Rohr UP, Hefter H. Frühe schmerzreduktion in der therapie von spastik nach einmaliger botulinustoxin-A-injektion. Dtsch Med Wochenschr 2001; 126: 1361-1364
13. Carruthers J, Carruthers A. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol 1992; 18: 17-21
14. Carruthers A, Langtry JA, Carruthers J, Robinson G. Improvement of tension-type headache when treating wrinkles with botulinum toxin A injections. Headache 1999; 39: 662-665
15. Krack P, Hornig C, Dorndorf W. Resolution of chronic tension-type headache after botulinum toxin treatment of idiopathic blepharospasm. Mov Disord 1995; 10: 388
16. Mense S. Neurobiologische grundlagen von muskelschmerz. Schmerz 1999; 13: 3-17
17. Simons DG, Mense S. Understanding and measurement of muscle tone as related to clinical muscle pain. Pain 1998; 75: 1-17
18. Porta M, Perretti A, Gamba M, Luccarelli G, Fornari M. The rationale and results of treating muscle spasm and myofascial syndromes with botulinum toxin type A. Pain Digest 1998; 8: 346-352
19. Cui ML, Khanijou S, Rubino J, Aoki KR. Botulinum toxin A inhibits the inflammatory pain in the rat formalin model. New Orleans: Society for Neuroscience Annual Meeting, 2000: Poster 246.2
20. Dolly J, Ashton A, Evans D et al. Molecular action of botulinum neurotoxins: Role of acceptors in targetting to cholinergic nerves and in the inhibition of the release of several transmitters. In: Dowdall M, Hawthorne J (eds): Cellular and Molecular Basis of Cholinergic Function. Chichester: Ellis Horwood, 1987: 517-535
21. Puffer E, Lomneth R, Sarkar H, Singh B. Differential roles of developmentally distinct SNAP-25 isoforms in the neurotransmitter release process. Biochemistry 2001; 40: 9374-9378
22. Sala C, Adreose J, Fumagalli G et al. Calcitonin gene-related peptide: Possible role in formation and maintenance of neuromuscular junctions. J Neurosci 1995; 15: 520-528
23. Suzuki N, Hardebo JE, Kahrstrom J et al. Neuropeptide Y co-exists with vasoactive intestinal polypeptide and acetylcholine in parasympathetic cerebrovascular nerves originating in the sphenopalatine, otic and internal carotid ganglia of the rat. Neuroscience 1990; 36: 507-519
24. Welch M, Purkiss J, Foster K. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000; 38: 245-258
25. Ferrari M. Migraine. Lancet 1998; 351: 1043-1051
26. Binder WJ, Brin MF, Blitzer A et al. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: An open-label study. Otolaryngol Head Neck Surg 2000; 123: 669-676
27. Aoki K, Weber J, Patten P et al. United States Patent Number 6113915, Sep. 5, 2000
28. Wiegand H, Erdmann G, Wellhöner HH. 125 I-labelled botulinum A neurotoxin: Pharmacokinetics in cats after intramuscular injection. Naunyn Schmiedeberg's Arch Pharmacol 1976; 292: 161-165
29. Hagenah R, Benecke R, Wiegand H. Effects of type A Botulinum toxin on the cholinergic transmission at spinal Renshaw cells and on the inhibitory action at la inhibitory interneurones. Naunyn Schmiedeberg's Arch Pharmacol 1977; 299: 267-272
30. Filippi GM, Errico P, Santarelli R et al. Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol 1993; 113: 400-404
31. Rosales RL, Arimura K, Ikenaga S, Osame M. Extrafusal and intrafusal muscle effects in experimental botulinum toxin A injection. Muscle Nerve 1996; 19: 488-496
32. Guyer BM. Mechanism of botulinum toxin in the relief of chronic pain. Curr Rev Pain 1999; 3: 427-431
33. Humm A, Pabst C, Lauterburg T, Burgunder J. Enkephalin and aFGF are differentially regulated in rat spinal motoneurons after chemodenervation with botulinum toxin. Exp Neurol 2000; 161: 361-372
34. Priori A, Berardelli A, Mercuri B, Manfredi M. Physiological effects produced by botulinum toxin treatment of upper limb dystonia. Changes in reciprocal inhibition between forearm muscles. Brain 1995; 118: 801-807
35. Ärztliche Zentralstelle für Qualitätssicherung. Leitlinien-info. ÄZQ-Schriftenreihe, Band 1. München: Zuckerschwerdt, 1999: 62-68
36. Scottish intercollegiate guidelines network. SIGN Guidelines - An Introduction to SIGN Methodology for the Development of Evidence-based Clinical Guidelines. Edinburgh: SIGN Publication Number 39. SIGN Secretariat. Royal College of Physicians, 1999
37. Chan J, Brin M, Fahn S. Idiopathic cervical dystonia: Clinical characteristics. Mov Disord 1991; 6: 119-126
38. Lindeboom R, Brans J, Aramideh M et al. Treatment of cervical dystonia: A comparison of outcome measures for outcome assessment. Mov Disord 1998; 13: 706-712
39. Pal PK, Samii A, Schulzer M et al. Head tremor in cervical dystonia. Can J Neurol Sci 2000; 27: 137-142
40. Behari M. Botulinum toxin in the treatment of writer's cramp. J Assoc Physicians India 1999; 47: 694-698
41. Kunig G, Pogarell O, Oertel WH. Facial pain in a case of cranial dystonia: A case report. Cephalagia 1998; 18: 709-711
42. Comella C, Shannon K, Jaglin J. Extensor truncal dystonia: Successful treatment with botulinum toxin injections. Mov Disord 1998; 13: 552-555
43. Cordiviari C, Misra V, Catania S, Lees A. Treatment of dystonic clenched fist with botulinum toxin. Mov Disord 2001; 16: 907-913
44. Pacchetti C, Albani G, Martignoni E et al. "Off" painful dystonia in Parkinson's disease treated with botulinum toxin. Mov Disord 1995; 10: 333-336
45. Dressler D, Argyrakis A, Schönle PW et al. Botulinumtoxintherapie in der rehabilitationsneurologie. Nervenarzt 1996; 67: 686-694
46. Reichel G. Botulinum toxin for treatment of spasticity in adults. J Neurol 2001; 248 (Suppl 1): 25-27
47. Benecke R. Botulinum toxin treatment in spasticity of lower extremities. In: Jankovic J, Hallet M (eds): Therapy with Botulinum Toxin. New York: Marcel Dekker, 1994: 463-473
48. Bhakta B, Cozens JA, Bamford JM, Chamberlain MA. Use of botulinum toxin in stroke patients with severe upper limb spasticity. J Neurol Neurosurg Psychiatry 1996; 61: 30-35
49. Dunne JW, Heye N, Dunne SL. Treatment of chronic limb spasticity with botulinum toxin. J Neurol Neurosurg Psychiatry 1995; 58: 232-235
50. Pierson SH, Katz DI, Tarsy D. Botulinum toxin A in the treatment of spasticity: Functional implications and patient selection. Arch Phys Med Rehabil 1996; 77: 717-721
51. Wissel J, Muller J, Dressnandt J et al. Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manage 2000; 20: 44-49
52. Barwood S, Baillieu C, Boyd R et al. Analgesic effects of botulinum toxin A: A randomized, placebo-controlled clinical trial. Dev Med Child Neurol 2000; 42: 116-121
53. Grazko MA, Polo KB, Jabbari B. Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology 1995; 45: 712-717
54. Bakheit AM, Pittstock S, Moore AP et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol 2001; 8: 559-565
55. Bhakta B, Cozens JA, Chamberlain MA, Bamford JM. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: A randomized double-blind placebo controlled trial. J Neurol Neurosurg Psychiatry 2000; 69: 217-221
56. Hyman N, Barnes M, Bhakta B et al. Botulinum toxin (Dysport®) treatment of hip adductor spasticity in multiple sclerosis: A prospective, randomised, double-blind, placebo-controlled, dose ranging study. J Neurol Neurosurg Psychiatry 2000; 68: 707-712
57. Hong C, Simons D. Pathophysiologic and electrophysiologic mechanisms of myofascial trigger points. Arch Phys Med Rehabil 1998; 79: 863-872
58. Hubbard D, Berkoff G. Myofascial trigger points show spontaneous needle EMG activity. Spine 1993; 18: 1803-1807
59. Acquadro MA, Borodic GE. Treatment of myofascial pain with botulinum A toxin. Anesthesiology 1994; 80: 705-706
60. Cheshire WP, Abashian SW, Mann JD. Botulinum toxin in the treatment of myofascial pain syndrome. Pain 1994; 59: 65-69
61. Yue SK. Initial experience in the use of botulinum-toxin A for the treatment of myofascial related muscle dysfunctions. J Musculoscelet Pain 1995; 3 (Suppl 1): 22
62. Monsivais JJ, Monsivais DB. Botulinum toxin in painful syndromes. Hand Clin 1996; 12: 787-789
63. Alo KM, Yland MJ, Kramer DL et al. Botulinum toxin in the treatment of myofascial pain. The Pain Clinic 1997; 10: 107-116
64. Galate JF, Childers MK, Gnatz S. Effectiveness of botulinum toxin in refractory piriformis muscle syndrome. Arch Phys Med Rehabil 1997; 78: 1041
65. Wheeler AH, Goolkasian P, Gretz SS. A randomized, double-blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome. Spine 1998; 23: 1662-1666
66. Diaz JH, Gould HJ. Management of post-thoracotomy pseudoangina and myofascial pain with botulinum toxin. Anesthesiology 1999; 91: 877-899
67. Jordan SE, Ahn SS, Freischlag JA et al. Selective botulinum chemodenervation of the scalene muscles for treatment of neurogenic thoracic outlet syndrome. Ann Vasc Surg 2000; 14: 365-369
68. Lutze MA. CT-gestützte injektionen von botulinumtoxin A beim myofaszialen schmerzsyndrom. Schmerz 2000; Suppl 1: 91
69. Porta M. A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm. Pain 2000; 85: 101-105
70. Nouwen A, Bush C. The relationship between paraspinal EMG and chronic low back pain. Pain 1984; 20: 109-123
71. Foster L, Clapp L, Erickson M, Jabbari B. Botulinum toxin A and chronic low back pain: A randomized, double-blind study. Neurology 2001; 56: 1290-1293
72. Paulson GW, Gill W. Botulinum toxin is unsatisfactory therapy for fibromyalgia. Mov Disord 1996; 11: 459
73. Asherson RA, Pascoe L. The use of botulinum toxin-A in the treatment of patients with fibromyalgia. J Rheumatol 2001; 28: 1740
74. Göbel H, Petersen-Braun M, Soyka D. The epidemiology of headache in Germany: A nationwide survey of a representative sample on the basis of the headache classification of the International Headache Society. Cephalalgia 1994; 14: 97-106
75. Jensen R. Pathophysiological mechanisms of tension-type headache: A review of epidemiological and experimental studies. Cephalalgia 1999; 19: 602-621
76. Jensen R, Olesen J. Tension-type headache: An update on mechanisms and treatment. Curr Opin Neurol 2000; 13: 285-289
77. Olesen J. Clinical and pathophysiological observations in migraine and tension-type headache explained by integration of vascular, supraspinal and myofascial inputs. Pain 1991; 46: 125-132
78. Pikoff H. Is the muscular model of headache still viable? A review of conflicting data. Headache 1984; 24: 186-198
79. Zwart JA, Bovim G, Sand T, Sjaastad O. Tension headache: Botulinum toxin paralysis of temporal muscles. Headache 1994; 34: 458-462
80. Relja MA, Korsic M. Treatment of tension-type headache by local injection of botulinum toxin. Eur J Neurol 1997; 4 (Suppl 2): 71-73
81. Wheeler AH. Botulinum toxin A, adjunctive therapy for refractory headaches associated with pericranial muscle tension. Headache 1998; 38: 468-471
82. Göbel H, Lindner V, Krack P et al. Treatment of chronic tension-type headache with botulinum toxin. Cephalalgia 1999; 19: 455
83. Schulte-Mattler WJ, Wieser T, Zierz S. Treatment of tension-type headache with botulinum toxin: A pilot study. Eur J Med Res 1999; 4: 183-186
84. Relja MA, Korsic M. Treatment of tension-type headache by injections with botulinum toxin type A; a double-blind placebo-controlled study. Neurology 1999; 52 (Suppl 2): 203
85. Smuts JA, Baker MK, Smuts HM. Botulinum toxin type A as prophylactic treatment in chronic tension-type headache. Cephalalgia 1999; 19: 454
86. Porta M. A comparative trial of botulinum toxin A and methylprednisolone for the treatment of tension-type headache. Curr Rev Pain 2000; 4: 31-35
87. Relja MA. Treatment of tension-type headache with botulinum toxin: 1-year-follow-up. Cephalalgia 2000; 20: 336
88. Rollnik JD, Tanneberger O, Schubert M et al. Treatment of tension-type headache with botulinum toxin type A: A double-blind, placebo-controlled study. Headache 2000; 40: 300-305
89. Wollina U. Botulinum A toxin for wrinkles: Release from tension headache. J Eur Acad Dermatol Venereol 2000; 14: 142-143
90. Schmitt WJ, Slowey E, Fravi N et al. Effect of botulinum toxin A injections in the treatment of chronic tension-type headache: A double-blind, placebo-controlled trial. Headache 2001; 41: 658-664
91. Diener HC, Brune K, Gerber W et al. Behandlung der migräneattacke und migräneprophylaxe. Dtsch Ärztebl 1997; 94: 3092-3102
92. Nelson CF. The tension headache, migraine headache continuum: A hypothesis. J Manipulative Physiol Ther 1994; 17: 156-167
93. Brin MF, Swope DM, O'Brien C et al. Botox® for migraine: Double-blind, placebo-controlled, region-specific evaluation. Cephalalgia 2000; 20: 421-422
94. Mauskop A, Basdeo R. Botulinum toxin A is an effect prophylactic therapy of migraines. Cephalalgia 2000; 20: 422
95. Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache 2000; 40: 445-450
96. Smuts JA, Barnard PWA. Botulinum toxin type A in the treatment of headache syndromes: A clinical report of 79 patients. Cephalalgia 2000; 20: 332
97. Klapper JA, Mathew NT, Klapper A, Kailasam J. Botulinum toxin type A (BTX-A) for the prophylaxis of chronic daily headache. Cephalalgia 2000; 20: 291-292
98. Harris M, Feinmann C, Wise M, Treasure F. Temporomandibular joint and orofacial pain: Clinical and medicolegal management problems. Br Dent J 1993; 174: 129-136
99. Headache classification committee of the international headache society. Classification and diagnosis criteria for headache disorders, cranial neuralgia and facial pain. Cephalalgia 1988; 8 (Suppl 7): 1-92
100. Ginies PR, Fraimout JL, Kong A et al. Treatment of cluster headache by subcutaneous injection of botulinum toxin. 8. World Congress on Pain, 1996; Poster presentation: 50
101. Freund BJ, Schwartz M. The use of Botulinum toxin A in the treatment of refractory cluster headache: Case reports. Cephalalgia 2000; 20: 329-330
102. Girdler NM. Use of botulinum toxin to alleviate facial pain (letter). Brit J Hospital Med 1994; 52: 362-363
103. Finn S, Ryan P, Sleeman D. The medical management of masseteric hypertrophy with botulinum toxin. J Ir Dent Assoc 2000; 46: 84-86
104. Freund B, Schwartz M, Symington JM. Botulinum toxin: New treatment for temporomandibular disorders. Br J Oral Maxillofac Surg 2000; 38: 466-471
105. von Lindern J. Type A botulinum toxin in the treatment of chronic facial pain associated with temporo-mandibular dysfunction. Acta Neurol Belg 2001; 101: 39-41
106. Hobson DE, Gladish DF. Botulinum toxin injection for cervicogenic headache. Headache 1997; 37: 253-255
107. Freund BJ, Schwartz M. Treatment of whiplash associated neck pain with botulinum toxin-A: Report of 8 cases. J Rheumatol 1999; 26: 756-758
108. Freund BJ, Schwartz M. Treatment of chronic cervical-associated headache with botulinum toxin A: A pilot study. Headache 2000; 40: 231-236
109. Pollmann W, Keidel M, Pfaffenrath V. Headache and the cervical spine: A critical review. Cephalalgia 1997; 17: 801-816
110. Hoogerwerf WA, Pasricha PJ. Botulinum toxin for spastic gastrointestinal disorders. Baillieres Best Pract Res Clin Gastroenterol 1999; 13: 131-143
111. Cuillere C, Ductrotte P, Zerbib F et al. Achalasia: Outcome of patients treated with intrasphincteric injection of botulinum toxin. Gut 1997; 41: 87-92
112. Pasricha PJ, Ravich WJ, Hendrix TR et al. Intrasphincteric botulinum toxin for the treatment of achalasia. N Engl J Med 1995; 322: 774-778
113. Pasricha PJ, Miskovsky EP, Kalloo AN. Intrasphincteric injection of botulinum toxin for suspected sphincter of Oddi dysfunction. Gut 1994; 35: 1319-1321
114. Sherman S, Kopecky KK, Brashear A, Lehmann GA. Percutaneus celiac plexus block with botulinum toxin A did not help the pain of chronic pancreatitis. J Clin Gastroenterol 1995; 20: 343-344
115. Wehrmann T, Seifert H, Seipp M et al. Endoscopic injection of botulinum toxin for biliary sphincter of Oddi dysfunction. Endoscopy 1998; 30: 702-707
116. Muehldorfer S, Hahn E. Botulinum toxin injection as a diagnostic tool for verification of Oddi dysfunction causing recurrent pancreatitis. Endoscopy 1997; 29: 120-124
117. Brisinda G, Maria G, Bentivoglio AR et al. A comparison of injections of botulinum toxin and topical nitroglycerin ointment for the treatment of chronic anal fissure. N Engl J Med 1999; 341: 65-69
118. Jost W. One hundred cases of anal fissure treatmed with botulin toxin: Early and long-term results. Dis Colon Rectum 1997; 40: 1029-1032
119. Maria G, Cassetta E, Gui D. A comparison of botulinum toxin and saline for the treatment of chronic anal fissure. N Engl J Med 1998; 338: 217-220
120. Christiansen J, Bruun E, Skjoldbye B, Hagen K. Chronic idiopathic anal pain: Analysis of ultrasonography, pathology, and treatment. Dis Colon Rectum 2001; 44: 661-665
121. Zermann D, Ishigoka M, Schubert J, Schmidt R. Perisphincteric injection of botulinum toxin type A. A treatment option for patients with chronic prostatic pain? Eur Urol 2000; 38: 393-399